Compare · DXCM vs GKOS
DXCM vs GKOS
Side-by-side comparison of DexCom Inc. (DXCM) and Glaukos Corporation (GKOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and GKOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 3.1x GKOS ($10.70B).
- DXCM has been more active in the news (9 items in the past 4 weeks vs 6 for GKOS).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Glaukos Corporation
- Price
- -
- -
- Market cap
- $33.65B
- $10.70B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2015
- News (4w)
- 9
- 6
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest GKOS
- Director Kliman Gilbert H exercised 2,500 shares at a strike of $25.77 and sold $475,000 worth of shares (2,500 units at $190.00) (SEC Form 4)
- Glaukos Announces Participation in Wells Fargo Healthcare Conference
- PRESIDENT & COO Gilliam Joseph E sold $10,784,659 worth of shares (60,000 units at $179.74) and exercised 60,000 shares at a strike of $52.94 (SEC Form 4)
- SVP & CHIEF FINANCIAL OFFICER Thurman Alex R. sold $3,602,600 worth of shares (20,000 units at $180.13) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $33.81 (SEC Form 4)
- Director Wen Leana sold $88,006 worth of shares (525 units at $167.63), decreasing direct ownership by 2% to 21,092 units (SEC Form 4)
- Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Glaukos Corporation
- Glaukos Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Glaukos Announces Second Quarter 2026 Financial Results
- UBS initiated coverage on Glaukos